Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARIA vs INCY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INCY Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

INCY Overall Winner 6-Pillar Tally: ARIA 0 – 6 INCY Matrix Metrics: ARIA 0 – 10 INCY

As of Nov 16, 2026, Incyte Genomics Inc (INCY) is the stronger overall head-to-head candidate over ARIA (ARIA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARIA carries a Unified Composite Score of 47.7/100 (HOLD) at $21.03 (N/M Forward P/E, N/A operating margin), whereas INCY carries 58.9/100 (HOLD) at $120.27 (13.9x Forward P/E, 32.2% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARIA vs INCY
ARIA US Equity
ARIA
Institutional Equity
$21.03
-3.52% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.92β · 43% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
INCY NASDAQ Head-to-Head Winner
Incyte Genomics Inc
Services-Commercial Physical & Biological Research
$120.27
-0.58% 1D
Market Cap $24.7B
TTM Revenue $6.01B
Forward P/E 13.9x
Beta / 30D Vol 0.30β · 35% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 52.8 · SMA20: $118.61 · SMA50: $119.05

6-Pillar Scorecard Institutional Category Breakdown (ARIA 0 – 6 INCY)

Columns: Metric · ARIA · INCY
1. Valuation Multiples INCY
Forward P/E N/M 13.9x
Trailing P/E N/M 61.7x
PEG Ratio N/M 10.82x
EV / Revenue N/M 3.6x
2. Growth & Scale INCY
Revenue Growth (YoY) N/A +14.0%
Earnings Growth (YoY) N/A +37.7%
TTM Revenue (USD) N/A $6.01B
Market Cap N/A $24.7B
3. Profitability & Quality INCY
Gross Margin N/A 56.0%
Operating Margin N/A 32.2%
Net Profit Margin N/A 6.7%
Return on Equity (ROE) N/A 7.8%
4. Balance Sheet & Cash Flow INCY
Cash Generation (TTM) N/A $680M
Cash Flow Margin N/A 11.3%
Net Cash / Leverage N/A ROE $3.24B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning INCY
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 41.7% (73rd %ile)
Put/Call OI Skew N/A 1.62x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat INCY
OpEx & R&D Intensity N/A 23.8% of Rev ($1.43B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARIA (0) vs INCY (10)
Institutional Metric ARIA INCY Criterion Row Edge
Market Capitalization
Scale
N/A $24.7B Larger Scale INCY
Trailing P/E Ratio
Valuation
N/M 61.7x Lower Multiple INCY
Forward P/E Ratio
Valuation
N/M 13.9x Lower Multiple INCY
Revenue Growth (YoY)
Growth
N/A +14.0% Higher Growth INCY
Operating Margin (TTM)
Profitability
N/A 32.2% Higher Margin INCY
Net Profit Margin
Profitability
N/A 6.7% Higher Margin INCY
Return on Equity (ROE)
Capital Efficiency
N/A 7.8% Higher ROE INCY
52-Week Range Position
Momentum
0% ($21–$27) 72% ($89–$133) Stronger Trend INCY
Beta / 30D Volatility
Risk Regime
1.92β · 43% Vol 0.30β · 35% Vol Lower Realized Risk INCY
Unified Institutional Score
Composite Signal
47.7 / 100 (HOLD) 58.9 / 100 (HOLD) Higher Composite INCY
Trailing 12M Revenue (USD)
Operating Scale
N/A $6.01B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 56.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 10.82x PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $680M ($3.24B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon INCY +17.92 pp
ARIA: -11.55% · INCY: +6.37%
3M Horizon INCY +13.62 pp
ARIA: -16.21% · INCY: -2.59%
6M Horizon INCY +15.92 pp
ARIA: -16.97% · INCY: -1.05%
1Y Horizon INCY +15.92 pp
ARIA: -16.97% · INCY: -1.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARIA vs INCY. Trailing 12-month operating profitability (ARIA N/A vs INCY 32.2%) and valuation multiples (ARIA N/M vs INCY 13.9x Forward P/E) are benchmarked directly in Pillar 4 below.

ARIA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
INCY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.01B
Gross Margin56.0%
Op. Margin32.2%
ROE / Fwd P/E7.8% · 13.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARIA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ARIA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INCY CONSOLIDATION
78d in phase · OBV DISTRIBUTION
Current IV 41.7%
IV Percentile 73rd %ile
Put/Call OI Skew 1.62x (Put-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact INCY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARIA Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
INCY Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $24.7B market capitalization and 32.2% operating margin.
OpEx & R&D Reinvestment 23.8% of Rev ($1.43B)
90D Engineering Disclosures 0 Published

Investor FAQ ARIA vs INCY Key Questions & Quantitative Answers

As of Nov 16, 2026, Incyte Genomics Inc (INCY) is the stronger overall head-to-head candidate over ARIA (ARIA) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARIA carries a Unified Composite Score of 47.7/100 (HOLD) at $21.03 (N/M Forward P/E, N/A operating margin), whereas INCY carries 58.9/100 (HOLD) at $120.27 (13.9x Forward P/E, 32.2% operating margin). Technically, ARIA sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure) and INCY sits in a Neutral phase (RSI 52.8, CONSOLIDATION options structure).

INCY leads the Growth & Scale pillar: ARIA posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with INCY at +14.0% YoY revenue growth and +37.7% YoY earnings growth on $6.01B TTM revenue (56.0% gross margin, 32.2% operating margin). On trailing 12-month operating scale, ARIA generates N/A in USD-normalized revenue versus $6.01B for INCY. In operating R&D and SG&A reinvestment, ARIA deploys N/A (0 90-day corporate R&D disclosures) versus 23.8% of Rev ($1.43B) (0 disclosures) for INCY.

INCY screens cheaper on headline valuation multiples. ARIA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas INCY trades at 13.9x Forward P/E, 61.7x Trailing P/E, 10.82x PEG, and 3.6x EV/Revenue (11.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARIA (N/A ROE) versus INCY (7.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ARIA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.92β · 43% Vol realized risk). By comparison, INCY carries 41.7% implied volatility (73rd %ile, Elevated (60th–80th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.30β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.